Insights into IMUNON's Ovarian Cancer Research Event
IMUNON, Inc. (NASDAQ: IMNN), a pioneering biotechnology firm focused on clinical-stage development, is thrilled to announce its first-ever Ovarian Cancer R&D Day, set for September 18, 2024. This event will take place at the esteemed Harvard Club in New York City and will provide a comprehensive look at IMNN-001, their investigational therapy targeting advanced ovarian cancer.
Event Highlights and Objectives
The R&D Day will thoroughly explore the potential of IMNN-001, featuring updates from leading experts and engaging discussions. Attendees will have the opportunity to hear from distinguished clinical study investigators, immunology specialists, biostatistics authorities, and IMUNON's executive management team. The event is designed to promote collaboration and understanding, running from 10:00 AM to 12:00 PM, followed by lunch and informal discussions.
Positive Developments from the OVATION 2 Study
In light of IMUNON's recent successes, the agenda will include significant updates regarding the randomized Phase 2 OVATION 2 Study, where IMNN-001 showed impressive results. This study revealed an 11.1-month improvement in median overall survival for patients, translating to a 35% increase in survival rates for those facing advanced ovarian cancer.
Expert Presentations to Share Valuable Insights
The day's presentations will feature a lineup of experts who are at the forefront of ovarian cancer research. Dr. Sid Kerkar will discuss the crucial role of IL-12 in cancer therapy. Following him, Dr. William Bradley will present safety and efficacy data for IMNN-001, providing valuable insights into its clinical relevance.
In-Depth Exploration of Clinical Findings
Dr. L.J. Wei will explain how a combined evaluation of progression-free survival (PFS) and overall survival (OS) can yield critical insights into treatment effects. Additionally, Dr. Amir Jazaeri will share findings from his ongoing Phase 1/2 study of IMNN-001 in combination with bevacizumab.
Finally, Dr. Premal Thakker will present the topline results from the OVATION 2 study, offering a deeper understanding of its clinical significance and enhancing IMNN-001's position among therapeutic options.
Company Leadership Engages with the Community
IMUNON’s leadership team will take the stage to outline future plans. Dr. Stacy R. Lindborg will emphasize treatment pathways for newly diagnosed ovarian cancer patients, highlighting IMNN-001's potential to revolutionize current therapeutic approaches and announcing plans for a Phase 3 registration study.
Dr. Khursheed Anwar will also discuss advancements within the company's TheraPlas platform technology, adding further innovation to their therapeutic development pipeline.
Understanding the Value of Ovarian Cancer Research
Ovarian cancer is one of the most lethal cancers affecting women in the U.S., with around 20,000 new cases diagnosed each year, many at advanced stages. There is an urgent need for innovative therapies that can reduce recurrence rates and significantly enhance overall survival.
IMUNON's strategies focus on regional targeting of immune modulation within the peritoneal cavity, which is critical for patients suffering from advanced ovarian cancer.
About IMNN-001
IMNN-001 is a groundbreaking immunotherapy developed using IMUNON's proprietary TheraPlas platform. This treatment utilizes an IL-12 DNA plasmid vector delivered via a nanoparticle system, which boosts the immune response by encouraging the body to produce powerful cancer-fighting proteins directly at tumor sites.
Moving Forward with Research and Innovation
IMUNON remains committed to advancing biotechnology through its ongoing clinical trials and the development of therapies aimed at complex medical conditions. In addition to IMNN-001, the company is investigating various modalities, including efforts related to viral antigens to elicit stronger immunological responses.
Join IMUNON for This Important Event
IMUNON invites both in-person attendees and those unable to attend to register for the event and access a live webcast. This is a unique opportunity to learn and engage with pioneering researchers and company leaders about exciting advancements in ovarian cancer treatment.
Frequently Asked Questions
What is the purpose of IMUNON's Ovarian Cancer R&D Day?
The event aims to share insights and updates regarding IMNN-001 and ongoing research efforts in the field of ovarian cancer treatment.
What are the highlights of the OVATION 2 Study?
The study reported an 11.1-month increase in median overall survival for patients treated with IMNN-001 compared to standard care approaches.
Who will be presenting during the event?
The event will feature several experts, including leading clinical study investigators and medical authorities in immunology.
How does IMNN-001 work?
IMNN-001 is designed to stimulate the immune response by encoding IL-12 in a nanoparticle delivery system, targeting treatment directly at tumor sites.
How does one register for the event?
Interested individuals can register for in-person attendance or access the webcast through the provided registration link.
